BRD4 and colorectal carcinoma: Notably, expression of BRD4 in tumor-associated type 2 macrophages is crucial in promoting their persistence with the tumor microenvironment and conferring resistance of CRC cells to oxaliplatin, a finding that seems to rely on the ability of BRD4 to enhance the transcription of SERPINE1 gene and, hence, production of plasminogen activator inhibitor-1 (PAI-1) (Pan et al., 2025), a well-known promoter of tumorigenesis (Placencio and DeClerck, 2015).